Core Viewpoint - Weikang Pharmaceutical faces administrative penalties from the Zhejiang Securities Regulatory Bureau for information disclosure violations, including non-disclosure of related party non-operating fund occupation and inaccuracies in convertible bond prospectus [1][2][5] Group 1: Administrative Penalties - The Zhejiang Securities Regulatory Bureau plans to impose a total fine exceeding 14 million yuan on Weikang Pharmaceutical and its responsible individuals, including a 5 million yuan fine on the company and a 7 million yuan fine on its actual controller Liu Zhongliang [1][5] - Liu Zhongliang, who served as the chairman from March 2015 until May 2024, has retired and is no longer involved in the company [1][2] Group 2: Fund Misappropriation - Liu Zhongliang directed Weikang Pharmaceutical to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal account, constituting non-operating fund occupation [2][3] - From 2018 to 2020, Liu Zhongliang borrowed 56.29 million yuan from the company to support a friend's new drug development, which was used for various personal and business expenses [2][3] Group 3: Financial Performance - Weikang Pharmaceutical's net profit has declined since its IPO in 2020, with losses reported in 2023 and the first quarter of 2025, showing a significant drop in revenue and profitability [6][7] - The company's gross margin has decreased from 72.41% in 2020 to 50.39% in 2023, attributed to a decline in high-margin prescription drug sales and increased costs [7] Group 4: Future Outlook - Liu Zhongliang expressed optimism about the company's future, focusing on the development and production of traditional Chinese medicine products, believing that difficulties are temporary and new growth will emerge in two to three years [7]

证券代码： 300878 证券简称：维康药业 浙江维康药业股份有限公司 投资者关系活动记录表 尊敬的投资者，您好！公司建立了较为完善的新药研发体系， 选题前做充分的市场调研，工艺研究、质量研究、药理毒理研究、 临床研究，小试、中试等各阶段严格控制，同时加大研发投入和 研发人才引进力度，力求尽量降低产品研发风险。感谢您对公司 的关注！ 3、公司在研发方面具备哪些优势？ 尊敬的投资者，您好！公司积极重视研发体系建设，先后成 立了省级高新技术企业研究开发中心、省级企业技术中心、省级 企业研究院、浙江省院士专家工作站、浙江省博士后工作站等多 个科研平台。2021 年，诺贝尔化学奖获得者迈克尔·莱维特教授 在公司成立诺贝尔奖工作站并受聘担任公司首席科学家，公司 "浙江省现代中药创新重点企业研究院"被认定为省重点企业研 究院。 此外，截至 2024 年末，公司拥有药品批准文号 37 个，其中 银黄滴丸、罗红霉素软胶囊等产品拥有发明专利与核心技术。 感谢您对公司的关注！ 编号：2025-001 | | □特定对象调研 分析师会议 □ | | | --- | --- | --- | | 投资者关系活动 | 媒体采访 业绩说明 ...

Core Viewpoint - Weikang Pharmaceutical reported a decline in revenue and net profit for 2024, with a focus on enhancing operational management and expanding its marketing network in 2025 [1][4] Financial Performance - In 2024, Weikang achieved revenue of 351 million yuan and a net profit of -147 million yuan; in Q1 2025, revenue was 69.78 million yuan with a net profit of -9.85 million yuan [1] - The company recorded non-recurring gains of 88.25 million yuan from the sale of its subsidiaries, while also accounting for fixed asset impairment losses of 76.20 million yuan [1] R&D and Innovation - Weikang emphasizes R&D and has established multiple research platforms, collaborating with industry experts and academic institutions [2] - The company is focusing on innovative drug development, with ongoing projects including two Class 1 traditional Chinese medicine (TCM) innovations and several Class 2 and Class 3 TCM new drugs [2] Product Highlights - The core product, Yinhuang Diban, has shown significant clinical effectiveness in treating various throat infections and has completed successful clinical trials for new indications [3] - Yinhuang Diban has received multiple accolades, including being ranked first in the retail terminal adult cold medication category in 2024 [3] Future Strategy - In 2025, Weikang plans to enhance its core business direction, improve operational management, and strengthen its marketing network to achieve performance targets [4] - The company aims to continue its focus on the health industry and cultivate new growth points aligned with its development strategy [4]

4月28日晚，维康药业（300878）(300878.SZ)发布2024年年度报告及2025年第一季度报告。财报显示， 2024年公司实现营业收入3.51亿元，归母净利润-1.47亿元；2025年一季度实现营业收入6977.59万元， 归母净利润-985.47万元。 对于此次业绩，维康药业表示主要归于以下几点原因，一是公司于2024年9月完成了从事医药零售业务 的全资孙公司浙江维康和浙江维康大药房的股权转让，取得投资收益8824.92万元，形成非经常性损 益，同时计提固定资产减值准备7620.28万元；二是公司产品销售收入和毛利率均有所下滑；三是公司 产品销售退回影响了2024年度特别是2024年四季度的收入和利润数据；四是公司医药大健康产业园一 期、二期固定资产折旧增加较多影响公司利润。 尽管面临上述挑战，维康药业仍通过研发创新及核心单品突破，持续强化技术壁垒。叠加中药行业政策 红利释放及成本端压力缓解，公司业绩有望逐季修复，步入高质量发展新阶段。 注重研发创新，技术壁垒持续强化 维康药业长期聚焦于新药研发和重点产品的二次开发，邀请了包括多名院士在内的行业权威教授、研究 员担任技术与研发顾问，并与高校、院士 ...